215
Views
23
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications

, , , &
Pages 1961-1968 | Accepted 19 Sep 2005, Published online: 28 Oct 2005
 

ABSTRACT

Objective: Transdermal delivery of fentanyl has potential benefits over slow-release morphine, being largely preferred by patients owing to the combination of effective pain relief, a good safety profile and easy, pain-free dosing. The new drug-in-adhesive Durogesic D-TRANS fentanyl Matrix Delivery System (DDTDF) has improved pharmaceutical characteristics and patient acceptability compared to the original Durogesic transdermal reservoir system (fentanyl transdermal reservoir), whilst still providing reliable and consistent delivery of fentanyl. The bioequivalence of these two systems was evaluated in two studies.

* Durogesic and D-TRANS are registered trade marks of ALZA Corporation, Mountain View, CA, USA

† Durogesic and D-TRANS are registered trade marks of ALZA Corporation, Mountain View, CA, USA

Research designs and methods: Eighty healthy volunteers received single (72 h) or multiple (288 h) applications of DDTDF and the transdermal reservoir system (100 µg/h) in two separate randomised, crossover bioequivalence studies. Bioequivalence was assessed by calculating the ratio of least squares means based on log-transformed data following single system application and at steady-state during the fourth application.

Results: Both transdermal systems were bioequivalent with respect to all tested pharmacokinetic parameters. Inter-subject variability was comparable between the two systems and was greater than intra-subject variability. Transdermal delivery was well tolerated in both groups.

Conclusions: The pharmacokinetic results demonstrate that DDTDF is bioequivalent to the original fentanyl transdermal reservoir system after single and multiple applications.

Notes

* Durogesic and D-TRANS are registered trade marks of ALZA Corporation, Mountain View, CA, USA

† Durogesic and D-TRANS are registered trade marks of ALZA Corporation, Mountain View, CA, USA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.